BioNTech (BNTX) Stock Analysis & Forecast

Nov 13 close

$85.60+0.56 (+0.7%)

Gekko Brief

Nov 9 close

BioNTech closed at $87.51 on 9 November 2026, 0% on the day. The price sits below both the 50-day ($94.37) and 200-day ($96.36) moving averages, inside a 52-week range of $79.52 to $124.00. The GekkoIndex reads 61.1, in the Accumulation zone, down 3 points over five sessions. Gekko Fair Value is $84.13, so the price is 4% above it.

The next earnings report is due on 9 March 2027, 114 days away (before open). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 4.1% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +6% over the last 5 years, rising in 3 of them.

16 firms rate the stock: 12 buy, 4 hold and 0 sell, with a consensus target of $116.30. A typical daily move is about 3.2%, and a typical 20-day move about 7.4%. On the swing-trade checklist, 4 items read supportive and 1 reads as a headwind (trend).

A plain summary of the figures as of the Nov 9, 2026 close.

BioNTech price vs fair value

$85.60$82.63Nov ’25May ’26Nov ’26
Close $85.60200-day averageGekko Fair Value $82.63

BioNTech quick facts

Market cap
$21.22B
P/E ratio
—
Forward P/E
7
EPS, TTM
−$6.81
Revenue, TTM
$2.42B
Profit margin
-60.9%
Dividend yield
—
Beta
1.33
Volume
843,711 avg 1.02M
1-year return
−23.4%
Typical daily move
±3.1%
Typical 20-day move
±7.4%
50-day average
$93.08
200-day average
$95.74
Next earnings
Mar 9 before open
Shares outstanding
247.9M
52-week range
$79.52$124.00

BioNTech swing-trade checklist

BioNTech scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $85.60 is below the 50-day ($93.08) and 200-day ($95.74) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    64.1, Accumulation

    Reading 64.1 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuemixed

    3.6% above

    Price is within 5% of Gekko Fair Value (3.6% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 114 days

    Next report Mar 9, 2027, 114 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.5% on average

    From this point in the calendar, the next 20 trading days averaged +3.5% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

BioNTech stock chart and price history

BioNTech closed at $85.60 on Nov 13, 2026, −23.4% over the past year, inside a 52-week range of $79.52 to $124.00.

Close50-day average200-day averageVolume
BioNTech share price, past year, with 50-day and 200-day moving averages and volume$90$100$110$120DecJan 2026FebMarAprMayJunJulAugSepOctNov85.60

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−5.1%
3 months
−6.6%
6 months
−4.4%
1 year
−23.4%
The full BNTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BNTX in Gekko

Follow BioNTech through every session

Put BNTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BNTX in GekkoFree for 7 days. No credit card required.

About BioNTech

BioNTech develops immune-based treatments aimed at cancer and infectious disease. It is widely recognized for its work on cancer vaccines and personalized immunotherapies designed to help the body's own immune system target tumors, alongside preventative vaccines addressing illnesses such as COVID-19 and influenza. Its research also extends to protein replacement approaches for rare conditions.

The company's pipeline spans several distinct treatment classes, including cancer vaccine candidates, neoantigen-targeted therapies, mRNA-based immunotherapies delivered directly into tumors, engineered immune cell treatments, checkpoint modulators, antibody-based candidates and small molecule compounds, most still moving through early to mid-stage clinical trials. To carry this work forward, BioNTech works alongside other pharmaceutical and biotechnology organizations, among them Genentech, Sanofi, Genmab, Pfizer, Shanghai Fosun Pharmaceutical and Regeneron.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany. Its shares trade under the ticker BNTX.

Sector
Health technology
Website
biontech.de

BioNTech GekkoIndex: the smart money zone

BioNTech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.1, in the Accumulation zone, up 2 points over five sessions.

010064.1Accumulation

Up 2 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying20+3.6%+6.3%+6.0%+17.3%
Accumulation (current zone)236+0.3%+1.0%+3.7%+6.6%
Neutral3700.0%−0.2%−1.1%−1.8%
Distribution25+0.1%−2.6%−4.9%−10.0%
Selling4Too few readings yet

Average BNTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the BNTX price, zone by zone.Track BNTX in Gekko

Is BioNTech stock overvalued? Gekko Fair Value

BioNTech trades 3.6% above Gekko Fair Value of $82.63, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what BioNTech shares are worth, recalculated every trading day.

$82.63

Gekko Fair Value, Nov 12, 2026

3.6% above fair value · About fair value

At the end of Aug 2026 the price was 17.3% above the estimate.

Gekko Fair ValueShare price, month end
$83$88Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BNTX in Gekko

BioNTech insider and Congress trading

No open-market insider purchases were filed for BioNTech, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BNTX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BNTX insider filing, plotted on the chart in Gekko.Open BNTX in Gekko

Congress trades last 90 days

No trades in BNTX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BNTX, plotted on the chart in Gekko.Open BNTX in Gekko

Unusual options activity last 30 days

2signals, 100% of the flagged premium in calls.

Latest: Bullish flow on Nov 13, $519K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

0of the funds Gekko tracks hold BNTX.

0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

BioNTech earnings: next date and track record

BioNTech reports on Mar 9, 2027, before the open (114 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±4.1%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−3.1%Aug ’24−0.5%Nov ’24−9.6%Mar ’25+3.5%Aug ’25+0.9%Nov ’25−11.1%Mar ’26−0.1%Aug ’26+3.6%Nov ’26

Last earnings call, Nov 3, 2026 AI summary

What they said
BioNTech reported Q3 2026 progress highlighting key oncology pipeline advances. Gotistobart nearly doubled median overall survival vs. standard-of-care chemotherapy in squamous non-small cell lung cancer. A new clinical collaboration with Gilead evaluates pumitamig combined with a TROP2-directed ADC in triple-negative breast cancer. Pumitamig plus LSD showed encouraging early efficacy in small cell lung cancer. CEO Uğur Şahin announced this was his final earnings call ahead of leadership transition to Guido Oelkers.
Guidance
BioNTech targets becoming a diversified multi-product company by 2030, with multiple pivotal trial readouts expected through 2030 across various tumor types. Management cited strong financial position and growing pipeline of potentially registrational trials supporting this trajectory.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 3, 2026$0.83
est $0.76
+9.2%$1.46B
est $1.17B
+24.8%+3.6%
Aug 4, 2026−$3.03
est −$2.58
−17.4%$120.6M
est $180.2M
−33.1%−0.1%
Mar 10, 2026−$1.44
est −$0.22
−556.7%$1.07B
est $902.3M
+18.1%−11.1%
Nov 3, 2025−$0.14
est −$1.12
+87.5%$1.78B
est $843.7M
+110.9%+0.9%
Aug 4, 2025−$1.82
est −$2.69
+32.3%$307.1M
est $177.8M
+72.7%+3.5%
Mar 10, 2025$1.15
est $0.46
+148.7%$1.23B
est $1.18B
+4.4%−9.6%
Nov 4, 2024$0.88
est −$1.70
+151.8%$1.39B
est $572.4M
+142.9%−0.5%
Aug 5, 2024−$3.36
est −$2.02
−66.3%$138.4M
est $145.4M
−4.8%−3.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

BioNTech stock forecast and analyst price targets

Analysts’ average 12-month price target for BioNTech is $113.50, +32.6% from the last close, from 16 firms rating the stock in the last 90 days.

$113.50consensus 12-month target, +32.6% from the last close
Low $86.86High $140
Buy12
Hold4
Sell0

Each firm’s latest rating in the last 90 days: 16 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11CitiBuy, maintained$125+46.0%
Nov 10H.C. WainwrightBuy, reiterated$110+28.5%
Nov 9Morgan StanleyBuy, reiterated$106+23.8%
Nov 9H.C. WainwrightBuy, maintained$110+28.5%
Nov 6BernsteinHold, maintained$96+12.1%
+3.7%average 20-day move after past Accumulation readings
+3.5%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

BioNTech seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, BioNTech averaged +3.5% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+10.5%2021+11.1%2022−3.5%2023+16.2%2024−9.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.6%1 of 5
Next 10 trading days+8.8%3 of 5
Next 15 trading days+4.7%4 of 5
Next 20 trading days+3.5%3 of 5
Next 30 trading days−1.9%2 of 5

For scale, BNTX’s typical 20-trading-day move in either direction is about 7.4%.

BioNTech market cap and key statistics

BioNTech’s market cap is $21.22B and revenue of $2.42B over the last twelve months.

Valuation

Market cap
$21.22B
Forward P/E
7
EPS, TTM
−$6.81
Gekko Fair Value
$82.63

Trading

Volume
843,711
Avg volume, 20 days
1.02M
52-week high
$124.00
52-week low
$79.52
Shares outstanding
247.9M

Financials

Revenue, TTM
$2.42B
Profit margin
-60.9%
Return on equity
-8.1%
Quarterly earnings growth, YoY
−43.2%

Risk and income

Beta
1.33
Typical daily move
±3.1%
Typical 20-day move
±7.4%

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

BioNTech stock FAQ

What is BioNTech’s market cap?

BioNTech’s market cap is $21.22B at the Nov 13, 2026 close of $85.60, with 247.9M shares outstanding.

What is the BioNTech stock forecast?

The consensus analyst 12-month price target for BioNTech is $113.50, +32.6% from the last close. Of the 16 firms that rated the stock in the last 90 days, 12 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is BioNTech stock overvalued or undervalued?

On Gekko’s estimate BioNTech is about fair value: the Nov 13, 2026 close of $85.60 is 3.6% above Gekko Fair Value of $82.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does BioNTech report earnings next?

BioNTech is expected to report on Mar 9, 2027, before the market opens (114 days away). Analysts expect earnings of −$1.89 per share on revenue of $426.3M. BioNTech beat the earnings estimate in 5 of its last 8 reports, moving 4.1% on average across the report.

What is BioNTech’s 52-week high and low?

BioNTech’s 52-week high is $124.00 and its 52-week low is $79.52; it closed at $85.60 on Nov 13, 2026, −23.4% over the past year. Over the last five years the shares peaked at $374.58 on Nov 29, 2021.

Is BioNTech stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, smart money, earnings risk and seasonality), 1 as mixed (fair value) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in BioNTech?

Gekko flagged 2 unusual options signals in BioNTech over the last 30 days, with $1.11M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 13, 2026 with $519K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See BioNTech the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.